Jin Rong Jie·2025-06-09 11:07Core Viewpoint - Junshi Bioscience's stock closed at 33.87 yuan, up 2.36%, with a latest price-to-book ratio of 5.94 and a total market capitalization of 33.385 billion yuan [1] Company Overview - Junshi Bioscience focuses on the research and development of new drugs, as well as related technology transfer and services, including the production and sales of new drugs [1] - The company's main products include Toripalimab, Dihydrocodeine Bromide Tablets, Tifcemalimab, Adalimumab, and several monoclonal antibodies targeting various diseases [1] - Junshi Bioscience holds 175 authorized patents, with 129 domestic and 46 international patents, providing extensive and long-term patent protection for its products [1] Financial Performance - For Q1 2025, Junshi Bioscience reported revenue of 501 million yuan, a year-on-year increase of 31.46% [1] - The net profit for the same period was -234.88 million yuan, reflecting a year-on-year change of 17.01% [1] - The company's gross profit margin stood at 81.24% [1] Institutional Holdings - As of Q1 2025, 15 institutions held shares in Junshi Bioscience, including 12 funds and 3 other entities, with a total holding of 185.09 million shares valued at 5.571 billion yuan [1]